Epidemiology of synchronous brain metastases
- PMID: 32363344
- PMCID: PMC7182307
- DOI: 10.1093/noajnl/vdaa041
Epidemiology of synchronous brain metastases
Abstract
Background: The objectives of this study were to characterize (1) epidemiology of brain metastases at the time of primary cancer diagnosis, (2) incidence and trends of synchronous brain metastases from 2010 to 2015, and (3) overall survival (OS) of patients with synchronous brain metastases.
Methods: A total of 42 047 patients with synchronous brain metastases from 2010 to 2015 were identified from the Surveillance, Epidemiology, and End Results database. Descriptive analysis was utilized to analyze demographics and incidence. The Kaplan-Meier method and a Cox proportional hazards model were utilized to evaluate potential prognostic factors for OS.
Results: The majority of patients were diagnosed from age older than 50 (91.9%). Common primary sites included lung (80%), melanoma (3.8%), breast (3.7%), and kidney/renal pelvis (3.0%). Among pediatric patients, common primaries included kidney/renal pelvis and melanomas. The incidence was roughly 7.3 persons/100 000. Synchronous brain metastases were associated with significantly poorer OS compared to extracranial metastases alone (hazard ratio [HR] =1.56; 95% CI: 1.54-1.58; P < .001). Among patients with brain metastases, male gender (HR = 1.60 vs 1.52), age older than 65 years (HR = 1.60 vs 1.46), synchronous liver, bone, or lung metastases (HR = 1.61 vs 1.49), and earlier year of diagnosis (HR = 0.98 for each year following 2010) were associated with significantly poorer OS.
Conclusions: The vast majority of brain metastases are from lung primaries. Synchronous brain metastases are associated with poorer OS compared to extracranial metastases alone.
Keywords: brain metastases; cancer; epidemiology; incidence; prognosis.
© The Author(s) 2020. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.
Figures



Similar articles
-
Epidemiology and survival outcomes of synchronous and metachronous brain metastases: a retrospective population-based study.Neurosurg Focus. 2023 Aug;55(2):E3. doi: 10.3171/2023.5.FOCUS23212. Neurosurg Focus. 2023. PMID: 37527669
-
Prognostic Value of Site-Specific Metastases and Therapeutic Roles of Surgery and Chemotherapy for Patients With Metastatic Renal Pelvis Cancer: A SEER Based Study.Technol Cancer Res Treat. 2021 Jan-Dec;20:15330338211004914. doi: 10.1177/15330338211004914. Technol Cancer Res Treat. 2021. PMID: 33929915 Free PMC article.
-
Epidemiological trends, prognostic factors, and survival outcomes of synchronous brain metastases from 2015 to 2019: a population-based study.Neurooncol Adv. 2023 Mar 5;5(1):vdad015. doi: 10.1093/noajnl/vdad015. eCollection 2023 Jan-Dec. Neurooncol Adv. 2023. PMID: 36968289 Free PMC article.
-
Lung-molGPA Index Predicts Survival Outcomes of Non-Small-Cell Lung Cancer Patients with Synchronous or Metachronous Brain Metastases.Onco Targets Ther. 2020 Sep 4;13:8837-8844. doi: 10.2147/OTT.S255478. eCollection 2020. Onco Targets Ther. 2020. PMID: 32943887 Free PMC article.
-
Prognostic factors and survival according to tumour subtype in women presenting with breast cancer bone metastases at initial diagnosis: a SEER-based study.BMC Cancer. 2020 Nov 13;20(1):1102. doi: 10.1186/s12885-020-07593-8. BMC Cancer. 2020. PMID: 33187507 Free PMC article.
Cited by
-
Clinical Practice Guidelines for Brain Metastasis From Solid Tumors.Brain Tumor Res Treat. 2024 Jan;12(1):14-22. doi: 10.14791/btrt.2023.0049. Brain Tumor Res Treat. 2024. PMID: 38317485 Free PMC article. Review.
-
TME-targeted approaches of brain metastases and its clinical therapeutic evidence.Front Immunol. 2023 May 9;14:1131874. doi: 10.3389/fimmu.2023.1131874. eCollection 2023. Front Immunol. 2023. PMID: 37228619 Free PMC article. Review.
-
Stereotactic Radiosurgery for a Patient With 94 Brain Metastases in the Setting of Prior Whole Brain Radiation.Cureus. 2025 Jun 28;17(6):e86925. doi: 10.7759/cureus.86925. eCollection 2025 Jun. Cureus. 2025. PMID: 40726868 Free PMC article.
-
Routine Neuroimaging in Patients with Stage IV Non-Small Cell Lung Cancer: A Single Center Experience.Curr Oncol. 2021 Mar 2;28(2):1125-1136. doi: 10.3390/curroncol28020108. Curr Oncol. 2021. PMID: 33801445 Free PMC article.
-
Treatment of Brain Metastases: The Synergy of Radiotherapy and Immune Checkpoint Inhibitors.Biomedicines. 2022 Sep 7;10(9):2211. doi: 10.3390/biomedicines10092211. Biomedicines. 2022. PMID: 36140312 Free PMC article. Review.
References
-
- Johnson JD, Young B. Demographics of brain metastasis. Neurosurg Clin N Am. 1996;7(3):337–344. - PubMed
-
- Nayak L, Lee EQ, Wen PY. Epidemiology of brain metastases. Curr Oncol Rep. 2012;14(1):48–54. - PubMed
-
- Fox BD, Cheung VJ, Patel AJ, Suki D, Rao G. Epidemiology of metastatic brain tumors. Neurosurg Clin N Am. 2011;22(1):1–6, v. - PubMed
-
- Bouffet E, Doumi N, Thiesse P, et al. . Brain metastases in children with solid tumors. Cancer. 1997;79(2):403–410. - PubMed
-
- Graus F, Walker RW, Allen JC. Brain metastases in children. J Pediatr. 1983;103(4):558–561. - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources